---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-25-000099"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:22:46.464257+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio Q1 GAAP net loss $426M on restructuring; consumable revenue record, non-GAAP loss narrows

## Summary
- Revenue $37.2M, down 4% YoY; consumable revenue record $20.1M (+26% YoY).
- GAAP net loss $426.1M ($1.44 EPS) includes $381.8M restructuring charges; non-GAAP net loss $44.4M ($0.15).
- Restructuring plan targets $45-50M annualized non-GAAP opex reduction by end of 2025; focuses on long-read business.
- Shipped 28 Vega and 12 Revio systems (Revio down from 28 YoY); non-GAAP gross margin improved to 40% from 33%.
- Independent investigation of employee allegations may delay Q1 10-Q filing; company sees no material financial impact.

## SEC filing metadata
- accession: 0001299130-25-000099
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000099/0001299130-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000099/pacb-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-25-000099
- JSON: https://secwatch.observer/filing/0001299130-25-000099.json
- Plain text: https://secwatch.observer/filing/0001299130-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.